Evidence Reviews und White Papers

Dokumente

Test Type

  • CRP
  • D-Dimer
  • INR
  • HbA1c
  • NT-proBNP
  • Point of care testing
  • SARS-CoV-2 Ab
  • SARS-CoV-2 Ag
  • SARS-CoV-2 Ag Pool
  • SARS-CoV-2 Ag Ultra
  • SARS-CoV-2 & Flu A/B

Comparability of LumiraDx glycated hemoglobin (HbA1c) measurement with capillary electrophoresis in use in a clinical core laboratory unit

Performance evaluation of the LumiraDx quantitative microfluidic point-of-care CRP test

Feedback on the Implementation of a Rapid and Connectable Point-of-Care COVID-19 Antigen Test in an Emergency Department

Clinical performance of five novel point-of-care D-Dimer devices with a capillary finger stick feature for predicting venous thromboembolism in general practice

Clinical Impact of point of care CRP testing in the Hospital@Home service

Uppsala University Validation of the Novel LumiraDx NT-proBNP Test in Primary Care

Analytical performance of the LumiraDX Point of care Method for the Measurement of C-Reactive Protein

Pre-evaluation of the LumiraDx HbA1c Test

AMR ViewPoint - use of CRP point of care testing in reducing antimicrobial prescribing in Primary Care

NT-proBNP - Klinisches Handout für Arztpraxis

D-Dimer- Klinisches Handout für Arztpraxen

Evaluation of LumiraDx POCT-Diagnostic-system CRP, D-Dimer and INR at the Centre of Laboratory Medicine in St. Gallen

Evaluation of LumiraDx POCT-Diagnostic-system SARS-CoV-2 Ag and Ab at the Centre of Laboratory Medicine in St. Gallen

Comparison between a laboratory and a point-of-care method for measuring C reactive protein (CRP)

Abstract Clinical Performance of the LumiraDx SARS-CoV-2 Ag Ultra Test

Performance Evaluation of the Microfluidic Antigen LumiraDx SARS-CoV-2 and Flu A/B Test in Diagnosing COVID-19 and Influenza in Patients with Respiratory Symptoms

D-Dimer Test - VTE in nur 6 Minuten zuverlässig ausschließen

Performance Evaluation of a new, microfluidic Point of Care Test for C Reactive Protein

Performance Evaluation of a Rapid Multiplex Point of Care SARS-CoV-2 Antigen and Flu A/B Test

Testing Times: Final report on the role of rapid diagnostics in tackling antimicrobial resistance (AMR)

Correlation of the Rapid Point of Care LumiraDx SARS-CoV-2 Antibody Test to Other SARS-CoV-2 Antibody Tests and to Viral Neutralization

Performance evaluation of a rapid multiplex point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 Antigen and Flu A/B

External Publication from BMJ Open: Narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients presenting with respiratory tract infections symptoms

LumiraDx SARS-CoV-2 Antibody Test Demonstrates High Sensitivity and Specificity in Point of Care Testing for COVID-19

LumiraDx SARS-CoV-2 Antigen Test Demonstrates High Sensitivity in Point of Care Testing for COVID-19

NHS Scotland Assessment of LumiraDx SARS-CoV-2 Ab Test

Performance evaluation of a rapid point-of-care microfluidic immunofluorescence assay for the detection of SARS-CoV-2 antibodies

COVID-19 Asymptomatic Testing with POC LumiraDx SARS-CoV-2 Antigen Test

LumiraDx SARS-CoV-2 Antigen (Ag) Test: Überlegene analytische Sensitivität im Vergleich zu mehreren Lateral Flow Tests

The quantitative LumiraDx D-Dimer Test provides lab-comparable results at the point of care

CTSB ermöglicht den nächsten Schritt zur Wiederaufnahme des normalen Lebens: Einsatz des LumiraDx SARS-CoV-2 Ag Pool Tests unterstützt Öffnungsstrategien für Publikumsveranstaltungen in Deutschland

Performance of a SARS-CoV-2 Antigen Pool Test to aid diagnosis of acute COVID-19 at the point of care

Performance evaluation of the quantitative point-of-care LumiraDx D-Dimer Test

The LumiraDx SARS-CoV-2 Antigen Test demonstrated as more sensitive compared to SD Biosensor Standard Q COVID-19 Rapid Antigen Test in an independent evaluation on behalf of the Swiss Federal Office of Public Health

Der LumiraDx SARS-CoV-2 Antigen Test eignet sich für den Nachweis infektiöser Proben von immunkompetenten Personen mit keinen bis milden und moderaten Symptomen

Summary of the Evaluation of 32 rapid tests for detection of IgG antibodies against SARS-CoV-2 (NOKLUS)

Establishing an Anticoagulation “Drive Through” Clinic during the COVID-19 Pandemic using the LumiraDx Platform INR Test

An evaluation of the detection of SARS-CoV-2 antigen in a cohort of symptomatic and asymptomatic patients: Report from the evaluation of SKUP

Performance evaluation of the LumiraDx SARS-CoV-2 Antigen Test to aid diagnosis of acute COVID-19 at the point of care

Evaluation of the Accuracy of the LumiraDx INR Test Using Patients in Receipt of Phenprocoumon Anticoagulation Therapy

Evaluation of the Accuracy of INR values measured by a POCT system in a German Clinic with patients taking Phenprocoumon as VKA Therapy.

Laboratory accuracy assessment of a novel INR Point-of-Care Test compared with laboratory reference methods used across four independent clinical sites.

Evaluation der Genauigkeit von LumiraDx INR-Messwerten bei Patienten unter Phenprocoumon-Therapie.

Sensitivity of LumiraDx INR Testing to Interference from Antiphospholipid Antibodies (aPL)

The LumiraDx Platform INR Test: Performance and ease of use in an anticoagulation clinic setting

LumiraDx INR Test: Laboratory Accuracy Assessment with the ACL Elite and Sysmex Reference Methods

Performance of the LumiraDx Platform INR Test in a point-of-care setting compared to an established laboratory reference method

Point of care testing in primary care in Europe: Improving pathways and patient outcomes

Point-of-care testing in the community pharmacy – improving access to care.

Bessere GesundheitErfahrungenOutcomes

Wir unterstützen ein gesünderes Leben für Einzelpersonen, Communities und die Gesellschaft als Ganzes.

Wir ermöglichen responsive, persönliche Beziehungen zwischen Patienten und Versorgungsteams.

Wir kontrollieren und senken Kosten zur Entlastung des Budgets von medizinischen Einrichtungen.

Informiert bleiben

FÜR NEWS ANMELDEN